Summit Therapeutics to Participate in 2018 BTIG Healthcare Conference
23 Février 2018 - 1:00PM
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug
discovery and development company advancing therapies for rare
diseases and infectious diseases, announces that management will
participate in one on one meetings at the 2018 BTIG Healthcare
Conference on 27 February 2018 in Snowbird, UT, US.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery,
development and commercialisation of novel medicines for
indications for which there are no existing or only inadequate
therapies. Summit is conducting clinical programs focused on the
genetic disease, Duchenne muscular dystrophy, and the infectious
disease, Clostridium difficile infection. Further information is
available at www.summitplc.com and Summit can be followed on
Twitter (@summitplc).
For more information, please contact:
Summit |
|
|
Glyn Edwards
/ Richard Pye (UK office) |
Tel: |
44 (0)1235 443 951 |
Erik Ostrowski /
Michelle Avery (US office) |
|
+1 617 225 4455 |
|
|
|
Cairn Financial
Advisers LLP (Nominated Adviser) |
Tel: |
+44 (0)20 7213
0880 |
Liam Murray / Tony
Rawlinson |
|
|
|
|
|
N+1
Singer (Joint Broker) |
Tel: |
+44 (0)20 7496
3000 |
Aubrey Powell / Jen
Boorer |
|
|
|
|
|
Panmure
Gordon (Joint Broker) |
Tel: |
+44 (0)20 7886
2500 |
Freddy Crossley,
Corporate Finance |
|
|
Tom Salvesen, Corporate
Broking |
|
|
|
|
|
MacDougall
Biomedical Communications (US) |
Tel: |
+1 781 235 3060 |
Karen Sharma |
|
ksharma@macbiocom.com |
|
|
|
Consilium
Strategic Communications (UK) |
Tel: |
+44 (0)20 3709
5700 |
Mary-Jane Elliott /
Jessica Hodgson / |
|
summit@consilium-comms.com |
Philippa Gardner /
Rosie Phillips |
|
|
-END-
Summit Therapeutics (NASDAQ:SMMT)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Summit Therapeutics (NASDAQ:SMMT)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024